Palo Alto Investors LP Purchases Shares of 33,640 Edwards Lifesciences Corporation $EW

Palo Alto Investors LP purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 33,640 shares of the medical research company’s stock, valued at approximately $3,043,074,000.

Several other institutional investors and hedge funds also recently modified their holdings of EW. BlackRock Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $5,318,092,000. State Street Corp raised its holdings in shares of Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 4.8% in the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after purchasing an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Edwards Lifesciences in the second quarter worth $1,274,082,000. Finally, Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth $803,686,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,857 shares of company stock valued at $170,305. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Mizuho boosted their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Truist Financial increased their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Piper Sandler restated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Trading Down 0.9%

NYSE EW opened at $89.97 on Friday. The company has a market cap of $51.81 billion, a PE ratio of 51.71, a PEG ratio of 2.38 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The stock has a 50 day moving average of $89.48 and a 200-day moving average of $84.99.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the company earned $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.